Publications by authors named "A A G A van de Munckhof"
Background: Cerebral venous thrombosis (CVT) accounts for 0.5-1% of all strokes. The role of endovascular therapy (EVT) in the management of CVT remains controversial and variations in practice patterns are not well known.
View Article and Find Full Text PDFArticle Synopsis
- The article has a Digital Object Identifier (DOI) that allows it to be easily found online.
- The DOI number given is 10.3389/fneur.2023.1251581.
- This correction is important for making sure the information in the article is accurate.
Introduction: Previous reports and meta-analyses derived from small case series reported a mortality rate of up to 40% in patients with coronavirus disease 2019 associated cerebral venous thrombosis (COVID-CVT). We assessed the clinical characteristics and outcomes in an international cohort of patients with COVID-CVT.
Patients And Methods: This was a registry study of consecutive COVID-CVT patients diagnosed between March 2020 and March 2023.
Article Synopsis
- The text outlines the challenges of conducting research on cerebral venous thrombosis (CVT) due to its rarity, emphasizing the need for a prioritized international research agenda to enhance prevention, diagnosis, and treatment for better patient outcomes.
- The agenda was developed during a summit in June 2023, involving 45 participants from 15 countries, including clinical researchers, former CVT patients, and representatives from funding organizations, focused on key research themes.
- It categorizes essential research questions into themes like epidemiology, diagnosis, medical treatment, and more, aiming to inspire future research, foster collaboration, and help secure funding to address these critical questions in CVT.
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare autoimmune condition associated with recombinant adenovirus (rAV)-based COVID-19 vaccines. It is thought to arise from autoantibodies targeting platelet factor 4 (aPF4), triggered by vaccine-induced inflammation and the formation of neo-antigenic complexes between PF4 and the rAV vector. To investigate the specific induction of aPF4 by rAV-based vaccines, we examined sera from rAV vaccine recipients (AZD1222, AD26.
View Article and Find Full Text PDF